secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-071974
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved
------------------------------------------------------------------------------

- Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).
- Royalty revenue from GSK $250.3M; IST U.S. net product sales $119.2M (+47% YoY).
- FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in Dec 2025.
- Guidance: IST U.S. net product sales at least $150M in 2026.
- $125M repurchase program initiated; 797,298 shares repurchased for $16.0M as of year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/0001193125-26-071974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/d23292d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-071974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer